More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura

Hematology

Volumn 21, Issue 5, 2016, Pages 311-316

  Vazquez Mellado, Alberto ^a   Pequeño Luévano, Myrna ^a   Cantu Rodriguez, Olga Graciela ^a   Villarreal Martínez, Laura ^a   Jaime Pérez, José Carlos ^a   Gomez De Leon, Andres ^a   De La Garza Salazar, Fernando ^a   Gonzalez Llano, Oscar ^a   Colunga Pedraza, Perla ^a   Sotomayor Duque, Guillermo ^a   Gomez Almaguer, David ^a  

^a HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

Author keywords

Adamts 13; Frontline therapy; Immunotherapy; Low dose rituximab; Plasma exchange; Rituximab; Thrombotic thrombocytopenic purpura; Ttp

Indexed keywords

HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADOLESCENT; ADULT; ARTICLE; AUTOIMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; FOLLOW UP; HUMAN; IMMUNOASSAY; IMMUNOSUPPRESSIVE TREATMENT; LOW DRUG DOSE; MALE; MIDDLE AGED; PLASMAPHERESIS; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RECURRENCE RISK; THROMBOCYTE COUNT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; YOUNG ADULT; DISEASE FREE SURVIVAL; MORTALITY; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; SURVIVAL RATE;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLASMA EXCHANGE; PURPURA, THROMBOTIC THROMBOCYTOPENIC; RITUXIMAB; SURVIVAL RATE;

EID: 84978464948     PISSN: 10245332     EISSN: 16078454     Source Type: Journal    
DOI: 10.1080/10245332.2015.1133008     Document Type: Article

References (23)

1. J.N.George. How I treat patients with thrombotic thrombocytopenic purpura. Blood. 2010;116(20):4060–9. doi: 10.1182/blood-2010-07-271445
2. E.Amorosi, J.Ultmann. Thrombotic thrombocytopenic purpura: report of 16 cases and review of the literature. Medicine. 1966;45(2):139–59. doi: 10.1097/00005792-196603000-00003
3. G.A.Rock, K.H.Shumak, N.A.Buskard, V.S.Blanchette, J.G.Kelton, R.C.Nair, Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian apheresis study group. N Engl J Med. 1991;325(6):393–7. doi: 10.1056/NEJM199108083250604
4. J.A.Kremer Hovinga, S.K.Vesely, D.R.Terrell, B.Lämmle, J.N.George. Survival and relapse in patients with thrombotic thrombocytopenic purpura. Blood. 2010;115(8):1500–11; quiz 662. doi: 10.1182/blood-2009-09-243790
5. M.J.Townsend, J.G.Monroe, A.C.Chan. B-cell targeted therapies in human autoimmune diseases: an updated perspective. Immunol Rev. 2010;237(1):264–83. doi: 10.1111/j.1600-065X.2010.00945.x
6. D.Provan, A.C.Newland, S.Amadori, R.Stasi. Rituximab in the treatment of autoimmune haematological disorders. Br J Haematol. 2008;143(2):294; author reply 5. doi: 10.1111/j.1365-2141.2008.07326.x
7. M.Scully, H.Cohen, J.Cavenagh, S.Benjamin, R.Starke, S.Killick, Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13. Br J Haematol. 2007;136(3):451–61. doi: 10.1111/j.1365-2141.2006.06448.x
8. J.M.Chemnitz, J.Uener, M.Hallek, C.Scheid. Long-term follow-up of idiopathic thrombotic thrombocytopenic purpura treated with rituximab. Ann Hematol. 2010;89(10):1029–33. doi: 10.1007/s00277-010-0968-3
9. A.Froissart, M.Buffet, A.Veyradier, P.Poullin, F.Provot, S.Malot, Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center. Crit Care Med. 2012;40(1):104–11. doi: 10.1097/CCM.0b013e31822e9d66
10. M.Pequeño-Luévano, L.Villarreal-Martínez, J.C.Jaime-Pérez, A.Gómez-de-León, O.G.Cantú-Rodríguez, O.González-Llano, Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: report of four cases. Hematology. 2013;18(4):233–6. doi: 10.1179/1607845412Y.0000000073
11. M.Scully, V.McDonald, J.Cavenagh, B.J.Hunt, I.Longair, H.Cohen, A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood. 2011;118(7):1746–53. doi: 10.1182/blood-2011-03-341131
12. J.P.Westwood, H.Webster, S.McGuckin, V.McDonald, S.J.Machin, M.Scully. Rituximab for thrombotic thrombocytopenic purpura: benefit of early administration during acute episodes and use of prophylaxis to prevent relapse. J Thromb Haemost. 2013;11(3):481–90. doi: 10.1111/jth.12114
13. V.McDonald, K.Manns, I.J.Mackie, S.J.Machin, M.A.Scully. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8(6):1201–8. doi: 10.1111/j.1538-7836.2010.03818.x
14. W.Barcellini, F.Zaja, A.Zaninoni, F.G.Imperiali, M.L.Battista, E.Di Bona, Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012;119(16):3691–7. doi: 10.1182/blood-2011-06-363556
15. F.Zaja, N.Vianelli, S.Volpetti, M.L.Battista, M.Defina, S.Palmieri, Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329–34. doi: 10.1111/j.1600-0609.2010.01486.x
16. W.Barcellini, F.Zaja, A.Zaninoni, F.G.Imperiali, E.Di Bona, B.Fattizzo, Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013;91(6):546–51. doi: 10.1111/ejh.12199
17. F.Zaja, M.L.Battista, M.T.Pirrotta, S.Palmieri, M.Montagna, N.Vianelli, Lower dose rituximab is active in adults patients with idiopathic thrombocytopenic purpura. Haematologica. 2008;93(6):930–3. doi: 10.3324/haematol.12206
18. D.Gómez-Almaguer, L.Tarín-Arzaga, B.Moreno-Jaime, J.C.Jaime-Pérez, A.A.Ceballos-López, G.J.Ruiz-Argüelles, High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90(6):494–500. doi: 10.1111/ejh.12102
19. D.Gómez-Almaguer, M.Solano-Genesta, L.Tarín-Arzaga, J.L.Herrera-Garza, O.G.Cantú-Rodríguez, C.H.Gutiérrez-Aguirre, Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783–5. doi: 10.1182/blood-2010-06-291831
20. M.Benjamin, D.R.Terrell, S.K.Vesely, G.W.Voskuhl, B.J.Dezube, J.A.Kremer Hovinga, Frequency and significance of HIV infection among patients diagnosed with thrombotic thrombocytopenic purpura. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2009;48(8):1129–37.
21. D.Hart, R.Sayer, R.Miller, S.Edwards, A.Kelly, T.Baglin, Human immunodeficiency virus associated thrombotic thrombocytopenic purpura – favourable outcome with plasma exchange and prompt initiation of highly active antiretroviral therapy. Br J Haematol. 2011;153(4):515–9. doi: 10.1111/j.1365-2141.2011.08636.x
22. M.Hie, J.Gay, L.Galicier, F.Provot, C.Presne, P.Poullin, Preemtive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. Blood. 2014;124(2):204. doi: 10.1182/blood-2014-01-550244
23. W.Lim, S.K.Vesely, J.N.George. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. Blood. 2015;125(10):1526–31. doi: 10.1182/blood-2014-10-559211